About
Junction Bioscience is building an autonomous AI scientist to navigate the discovery of transformative medicines. Our scientific hypothesis engine iterates upon breakthrough chemistry from the laboratory to achieve clarity and control over the molecular basis of disease. We focus on the intersection of neuroinflammation and immunology where uncommon molecular insights position us to develop best-in-class therapies for millions of patients in need. Junction Bioscience operates in healthcare. Headquarters: United States.
- Headquarters
- United States
- Founders
- Not disclosed
- Verified backers
- Not disclosed
- Industry
- Healthcare
Trade on Junction Bioscience
Junction Bioscience shares
No active listings yet.
Be the first to post →FAQ
Junction Bioscience private shares
Practical questions on buying, selling, and pricing Junction Bioscience stock in the secondary market.
How to buy Junction Bioscience shares?
Junction Bioscience is privately held, so there is no public ticker and no exchange order book. Stock typically changes hands when early investors, employees, or funds with existing positions decide to sell, often via a broker or a structured secondary. Transfers are usually subject to the company’s right of first refusal and other restrictions in the stockholders’ agreement. If you are eligible, you can post a buy request on Bubex so holders looking to exit Junction Bioscience can find you.
What is Junction Bioscience share price?
There is no official Junction Bioscience share price. Private names do not print a close. Indicative levels can be inferred from the last priced round, tender offers, and reported secondaries, but those prints are not executable quotes and they often disagree with one another. Cross-check platforms and brokers; the better execution is usually the one you actually get filled at, not the headline mark.
Are Junction Bioscience shares publicly traded?
No. Junction Bioscience is not listed on NYSE, Nasdaq, or any other public exchange. Any purchase is an off-exchange transfer of existing private stock (or an interest in a vehicle that holds it), not an IPO subscription.
When is the Junction Bioscience IPO?
Nobody knows. Junction Bioscience has not filed to go public, and private companies do not publish an IPO date in advance. Rumours, banker mandates, and “late 20XX” chatter are not a timetable — many names stay private, get acquired, or slip the listing by years. Until a registration statement is actually filed, treat any IPO date as unknown and use the secondary market if you need access before a listing.
Who can buy Junction Bioscience shares on the secondary market?
Secondary access to Junction Bioscience is generally limited to accredited investors and other eligible counterparties. Even then, the company or its transfer agent may need to approve the transferee. Bubex introduces buyers and sellers; it is not a broker-dealer and does not execute, custody, or settle the trade.
Can I sell Junction Bioscience shares?
Existing holders — typically employees after a vesting event, early investors, or funds — may be able to sell, subject to lock-ups, ROFR, and company policy. If you hold Junction Bioscience stock and want liquidity, you can post a sell offer on Bubex to find qualified buyers rather than waiting for a company-run tender.
How is Junction Bioscience valued if it is still private?
Private-market value is not a single number. Practitioners look at the last primary round, any 409A, reported tender prices, and implied marks from secondaries. Those inputs can diverge: secondaries often trade at a discount or, less often, a premium to the last round. Bubex surfaces the latest disclosed round and any market indications we can corroborate; treat them as context, not a valuation opinion.
What is the difference between Junction Bioscience’s last funding round and a secondary trade?
A funding round is a primary issuance: the company sells new shares and the post-money valuation is reset. A secondary trade is a transfer of shares already outstanding between two holders; it does not recapitalise Junction Bioscience the same way. Secondary price per share can therefore sit well away from the last-round mark, which is why you should not treat the headline valuation as your entry price.
Information and introductions only. Bubex does not provide investment advice, brokerage, execution, custody, or settlement. Secondary transfers remain subject to company consents and applicable securities law.